• Carmelina Cardiovascular Outcome Trial met its Primary Endpoint americanpharmaceuticalreview
    July 24, 2018
    Carmelina met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Trajenta (linagliptin) demonstrating similar cardiovascular safety compared to placeb
PharmaSources Customer Service